WASHINGTON, Dec. 16 /PRNewswire/ -- The Food and Drug Administration's
(FDA) approval today of Lunesta(TM) (eszopiclone) for the treatment of
insomnia coincides with a growing medical and scientific interest in this
Symptoms of insomnia are extraordinarily common. More than one-half of
America's adults, 58% or 126 million people, experience at least one symptom
of insomnia a few nights a week, according to NSF's 2002 Sleep in America
poll. Insomnia is more prevalent among older adults and women. It is a
frequent problem for individuals with a variety of medical and psychiatric
conditions, and in shift workers.
Insomnia can be primary (not associated with another medical condition or
disease), but is often associated with other health problems or disease
including pain, depression, heart disease and sleep disorders such as
obstructive sleep apnea and restless legs syndrome. Insomnia can also be
caused by certain medications and lifestyle factors. If insomnia persists, a
physician should be consulted to ensure that the sleep problem is not due to
another disease and to ensure that it does not become conditioned or habitual.
Chronic insomnia may be associated with impaired cognitive functions such as
memory and concentration, a higher risk of mental health problems, safety and
occupational concerns, and reduced quality of life.
Insomnia treatment includes the recommendation to adhere to the principles
of good sleep hygiene, including behavioral practices such as reducing
caffeine in the diet and establishing standard bedtimes. Healthcare
professionals may treat insomnia by behavioral and cognitive methods that
promote relaxation, increase the amount of bedtime actually spent sleeping,
and address maladaptive sleep expectations and attitudes like "I'll never fall
asleep." Pharmacotherapy, including use of hypnotic medications that reduce
time to fall asleep, increase total sleep time, reduce awakenings, and improve
sleep quality may be prescribed.
Based on published clinical reports, Lunesta(TM) is the first
pharmacological treatment that has demonstrated safety and efficacy of long-
term nightly use. According to Thomas Roth, PhD, a sleep researcher at the
Henry Ford Hospital, Detroit, "Lunesta(TM) helps patients fall asleep and stay
asleep throughout the night."
Comprehensive information about getting sufficient sleep, insomnia and
sleep disorders tailored to different age groups, genders and lifestyles can
be found at http://www.sleepfoundation.org.
The National Sleep Foundation is an independent nonprofit organization
dedicated to improving public health and safety by achieving understanding of
sleep and sleep disorders, and by supporting education, sleep-related research
Marcia C. Stein
(202) 347-3471 x205
SOURCE National Sleep Foundation